RedHill Biopharma (RDHL) Total Current Liabilities (2014 - 2025)

RedHill Biopharma (RDHL) has 12 years of Total Current Liabilities data on file, last reported at $19.2 million in Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $19.2 million, down 13.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.2 million (down 13.51% YoY), and the FY2025 annual result was $19.2 million, down 13.51% from the prior year.
• Total Current Liabilities slipped to $19.2 million in Q4 2025 per RDHL's latest filing, from $22.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $197.5 million in Q4 2022 and troughed at $19.2 million in Q4 2025.
• A 5-year average of $65.8 million and a median of $25.2 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 142.36% in 2022, then plunged 89.88% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $81.5 million in 2021, then soared by 142.36% to $197.5 million in 2022, then sank by 89.88% to $20.0 million in 2023, then gained by 11.21% to $22.2 million in 2024, then dropped by 13.51% to $19.2 million in 2025.
• Business Quant data shows RDHL's Total Current Liabilities at $19.2 million in Q4 2025, $22.3 million in Q2 2025, and $22.2 million in Q4 2024.